Literature DB >> 32393125

Advancing Value-Based Models for Heart Failure: A Call to Action From the Value in Healthcare Initiative's Value-Based Models Learning Collaborative.

Karen Joynt Maddox1, William K Bleser2, Hannah L Crook2, Adam J Nelson3, Marianne Hamilton Lopez2, Robert S Saunders2, Mark B McClellan2, Nancy Brown4.   

Abstract

Heart failure (HF) is a leading cause of hospitalizations and readmissions in the United States. Particularly among the elderly, its prevalence and costs continue to rise, making it a significant population health issue. Despite tremendous progress in improving HF care and examples of innovation in care redesign, the quality of HF care varies greatly across the country. One major challenge underpinning these issues is the current payment system, which is largely based on fee-for-service reimbursement, leads to uncoordinated, fragmented, and low-quality HF care. While the payment landscape is changing, with an increasing proportion of all healthcare dollars flowing through value-based payment models, no longitudinal models currently focus on chronic HF care. Episode-based payment models for HF hospitalization have yielded limited success and have little ability to prevent early chronic disease from progressing to later stages. The available literature suggests that primary care-based longitudinal payment models have indirectly improved HF care quality and cardiovascular care costs, but these models are not focused on addressing patients' longitudinal chronic disease needs. This article describes the efforts and vision of the multi-stakeholder Value-Based Models Learning Collaborative of The Value in Healthcare Initiative, a collaboration of the American Heart Association and the Robert J. Margolis, MD, Center for Health Policy at Duke University. The Learning Collaborative developed a framework for a HF value-based payment model with a longitudinal focus on disease management (to reduce adverse clinical outcomes and disease progression among patients with stage C HF) and prevention (an optional track to prevent high-risk stage B pre-HF from progressing to stage C). The model is designed to be compatible with prevalent payment models and reforms being implemented today. Barriers to success and strategies for implementation to aid payers, regulators, clinicians, and others in developing a pilot are discussed.

Entities:  

Keywords:  chronic disease; disease progression; heart failure; hospitalization; population

Year:  2020        PMID: 32393125     DOI: 10.1161/CIRCOUTCOMES.120.006483

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  4 in total

1.  Incidence of Timely Outpatient Follow-Up Care After Emergency Department Encounters for Acute Heart Failure.

Authors:  Austin S Kilaru; Nicholas Illenberger; Zachary F Meisel; Peter W Groeneveld; Manqing Liu; Angira Mondal; Nandita Mitra; Raina M Merchant
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-09-08

2.  Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018.

Authors:  Leah Rethy; Thanh-Huyen T Vu; Nilay S Shah; Mercedes R Carnethon; Tara Lagu; Mark D Huffman; Clyde W Yancy; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Circ Heart Fail       Date:  2022-04-28       Impact factor: 10.447

Review 3.  Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth.

Authors:  Ileana L Piña; Larry A Allen; Nihar R Desai
Journal:  J Card Fail       Date:  2021-09-11       Impact factor: 6.592

4.  Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial.

Authors:  Adam D DeVore; Bradi B Granger; Gregg C Fonarow; Hussein R Al-Khalidi; Nancy M Albert; Eldrin F Lewis; Javed Butler; Ileana L Piña; Larry A Allen; Clyde W Yancy; Lauren B Cooper; G Michael Felker; Lisa A Kaltenbach; A Thomas McRae; David E Lanfear; Robert W Harrison; Maghee Disch; Dan Ariely; Julie M Miller; Christopher B Granger; Adrian F Hernandez
Journal:  JAMA       Date:  2021-07-27       Impact factor: 56.272

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.